Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.
about
The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in miceExtraintestinal manifestations of inflammatory bowel disease: epidemiology, diagnosis, and management.Pyoderma gangrenosum as a first presentation of inflammatory bowel diseaseSclerosing mesenteritis successfully treated with a TNF antagonistNasal Crohn's disease /apheresisBiological therapy for dermatological manifestations of inflammatory bowel diseaseExtraintestinal manifestations of inflammatory bowel disease: do they influence treatment and outcome?Management of arthropathy in inflammatory bowel diseases.PTPN2 controls differentiation of CD4⁺ T cells and limits intestinal inflammation and intestinal dysbiosis.The role of tumour necrosis factor-α and tumour necrosis factor receptor signalling in inflammation-associated systemic genotoxicity.Management of Musculoskeletal Manifestations in Inflammatory Bowel DiseaseOff-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.Successful use of adalimumab for treating fistulizing Crohn's disease with pyoderma gangrenosum: Two birds with one stonePersistent retention of colitogenic CD4+ memory T cells causes inflammatory bowel diseases to become intractable.Oral manifestation in inflammatory bowel disease: a review.Protein kinase D mediates synergistic expression of COX-2 induced by TNF-{alpha} and bradykinin in human colonic myofibroblasts.Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease.Consensus guidelines for the management of inflammatory bowel disease.Use of biological molecules in the treatment of inflammatory bowel disease.Antitumor necrosis factor treatment for pediatric inflammatory bowel disease.Oxidative stress in ulcerative colitis: an old concept but a new concern.Anti-TNF Treatment for Extraintestinal Manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study.Chronological Order of Appearance of Extraintestinal Manifestations Relative to the Time of IBD Diagnosis in the Swiss Inflammatory Bowel Disease Cohort.Experimental colitis delays and reduces the severity of collagen-induced arthritis in mice.Steroid-refractory ulcerative colitis and associated primary sclerosing cholangitis treated with infliximab.Management of cutaneous disorders related to inflammatory bowel disease.Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis.Frequency and risk factors for extraintestinal manifestations in the Swiss inflammatory bowel disease cohort.Long-term durability of response to adalimumab in Crohn's disease.Evaluation of a daily practice composite score for the assessment of Crohn's disease: the treatment impact of certolizumab pegol.Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn's Disease: A Pooled Analysis of 11 Clinical Studies.A Synbiotic with Tumor Necrosis Factor-α Inhibitory Activity Ameliorates Experimental Jejunoileal Mucosal Injury.
P2860
Q30613139-1163DB4A-61B3-47A2-BA81-94BD15FC26C8Q33532262-B29BA4E6-161F-4307-B722-F370CE4E5E67Q34476959-83C436AF-1CFC-4026-A6DC-3D1A6270D585Q34532478-DEF4341D-5F6B-422F-8934-AFE2049F1773Q34940554-8CC6006D-BD64-4193-9803-A50B443F3CEEQ35058744-C1931BA0-5908-477F-A2F5-60DC2EC7FCBAQ35065315-B51ECB67-40E2-4C42-A35E-6517E761C5CBQ35091366-F7422077-6623-41C2-BD07-8BB9D87B0276Q35506437-801D6833-CEC7-4AA6-83B6-D9DCC36DDC4DQ35621836-A4A9956C-01F3-4F4D-ADF0-075100E55A70Q35773115-EC98BC08-E989-4DA1-9D25-396723DFFDF8Q37105146-176F5959-9744-44A7-B11D-947A443D14ACQ37192685-68DC3259-90F7-4C37-B98A-E76EFA6D3E81Q37325656-3E621844-EAD3-4935-9243-F99CA9699024Q37408829-39B4FCD9-0F90-4FE1-9313-401555AE6EFCQ37474532-C3F23D13-5050-4708-A26E-5136910F6B01Q37789689-84BEC905-B297-47E2-BAF4-4A6208564DA5Q37817803-0E9481B2-6236-49E1-AFB9-D28EF82104CAQ37829470-B9DAB7FD-7B2B-4C00-83A7-B6FC988FC3ABQ37936394-2A85038D-66D0-412F-B69F-BC56987591CCQ38031537-C5931E48-3113-4395-8BB2-7B5DB881804FQ38814948-B9ED0DAD-40F0-447D-AA0B-4B155A296815Q40893795-230E37A8-A0A4-40DC-8E23-235BB4936D8BQ41677436-C3B39F29-5C5E-4E25-8DA2-019AE56C8843Q42253760-9271981D-FC85-4925-B8C2-DEF78AD1A017Q42406766-E4DA7C8A-A2B7-41A1-881C-FE0DF4D1E285Q43066415-187FE9D7-2BFE-47D3-9CC1-6C5321E416A3Q45896089-4695890F-C8F7-401C-96B0-83621DE0BD92Q51164478-40DA3D34-853B-43E9-BD65-85E5714753B1Q51584924-915A6979-39BE-424E-9A14-F1D0638B24C9Q53838959-2B9325D0-1C00-403C-B086-56C2692F154BQ55003562-AB1360BE-893D-40E2-A779-B69DD0C6D92B
P2860
Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Biologic therapy in the manage ...... of inflammatory bowel disease.
@en
type
label
Biologic therapy in the manage ...... of inflammatory bowel disease.
@en
prefLabel
Biologic therapy in the manage ...... of inflammatory bowel disease.
@en
P2860
P356
P1476
Biologic therapy in the manage ...... of inflammatory bowel disease.
@en
P2093
Arthur Barrie
Miguel Regueiro
P2860
P304
P356
10.1002/IBD.20196
P577
2007-11-01T00:00:00Z